Aligning payer criteria with the FDA label, rather than the trial's narrower enrollment rules, may determine how many patients with this costly, progressive disease actually gain access to treatment.

The FDA label reaches further than the pivotal trial's inclusion criteria, and DUPLEX's own subgroup data reveals where the treatment effect holds strongest and where it does not.

Tiffany Phung, Pharm.D., CSP, of UC Davis Health, discusses an alternative approach to clinical research and practice improvement ahead of HSES 2026.

Continuing the Managed Healthcare Executive Between the Lines series, moderator Philip Mease, MD, of Swedish Medical Center, Providence St. Joseph Health, and the University of Washington, and guest Saakshi Khattri, MD, of the Icahn School of Medicine at Mount Sinai, shift from the broader disease burden discussion to how biologics are actually being used in practice today, before laying out the design of the BE BOLD trial.

Will Carroll, Pharm.D., chief pharmacy officer at Sutter Health, discusses strategic priorities and his vision for specialty pharmacy growth.

Joseph Savasta, founder and CEO of pharmacy benefit manager HarmonyRx, discusses why the company keeps rejecting acquisition offers amid PBM consolidation.

Patel, senior vice president of trade relations and supply chain at MedImpact, discusses his career path and current responsibilities. at MedImpact.

Robyn S. Crosson, J.D., VP of government relations at Navitus Health Solutions, has won the PBMI Innovators Award for her work advancing transparency in pharmacy benefits.

A closely watched safety profile and a REMS program built for vigilance define how clinicians should approach monitoring patients starting on this dual receptor antagonist.